Janssen returns NASH candidate rights to Arrowhead

16 February 2023
arrowhead-company

US biotech Arrowhead Pharmaceuticals (Nasdaq: AEWR) yesterday revealed receiving a written notice from US healthcare giant Johnson & Johnson’s (NYSE: JNJ) Janssen unit that it has terminated its rights to JNJ-75220795, now called ARO-PNPLA3, under the October 2018 research collaboration and option agreement, as part of J&J’s strategic R&D portfolio review.

The deal could have earned Arrowhead as much as $3.7 billion including milestone and royalty payments.

Arrowhead put a positive spin on the news that it now regained full rights to the non-alcoholic steatohepatitis (NASH) candidate, and saw its shares dip only 3% to $33.01 in after-hours trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology